2.
To understand the need to distinguish between Efficacy trials (which might reflect ideal circumstances) and Effectiveness trials (which assess effect in the "real world").
3. To identify the current knowledge and evidence gaps in strategies that have been considered to potentially prevent food allergy at a population level.
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2
Clinical trials are generally undertaken with significant resources, optimal conditions, and homogeneous participants with limited geographical and environmental variation. Such studies are efficacy trials-assessing the outcome of an intervention under ideal conditions. This is in contrast to effectiveness trials, which are performed under real-life, pragmatic conditions. It is insufficient to demonstrate that an intervention is successful within the confines of a randomized controlled trial (RCT) to ensure that it will be an effective intervention across the population at large.
3 Population-based interventions need to be assessed not only for level of evidence, applicability, and feasibility before recommendations are made, but they also need to be evaluated once implemented, such that their actual impact, and any unintended consequences (or harm), can be determined.
In this commentary, we discuss the main challenges and risks of using data from efficacy trials to develop public health interventions appropriate to the general population, and explore barriers to the successful implementation of measures to reduce the community burden of food allergy.
ASSESSING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS
The first requirement for any disease prevention program is ensuring the sensible and accurate translation of evidence arising from clinical trials into public health recommendations and policy. This is a complex process that is best approached in a systematic way. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group has developed a commonly used tool to evaluate the certainty of findings arising from a systematic review of the evidence, 4,5 and a separate tool to assist with making recommendations for treatment, diagnosis, or prevention.
6 These are summarized in Figure 1 . In brief, the available evidence for each outcome of interest is first assessed for quality, from very low to high, according to the confidence in the evidence. This may be downgraded because of variety of reasons as outlined in Table I . Once the quality of the evidence has been assessed and considered sufficiently robust to merit consideration for translation, the applicability to the wider population must then be evaluated (Table II) . A strong recommendation would be appropriate when most patients (or their families) would want the intervention, where the majority of clinicians agree that the intervention should be offered, and where the recommendations are acceptable as a public health measure to policy makers. 8 The GRADE framework has been used by the Allergic Rhinitis and its Impact on Asthma group and working groups within the World Allergy Organization (WAO), 9 and by WAO to make recommendations regarding the use of probiotics for allergic disease prevention.
10 However, with respect to food allergy prevention, although there have been several recommendations arising from national specialist organizations, it is not clear that any of these have yet undertaken this robust approach to formulating recommendations to be implemented at a population level. Table III summarizes existing synthesized evidence for food allergy prevention interventions of current high interest using the GRADE approach. Although it is beyond the scope of this review to discuss each intervention in detail, there are only a few interventions that currently have sufficient evidence to warrant consideration as a population-based implementation. These include early introduction of peanut and egg to the infant diet, 17 maternal probiotic supplementation during pregnancy and lactation, 10 and maternal fish oil supplementation during pregnancy. 11, 12, 14 The remainder of the synthesized evidence to date shows low or no evidence when assessed using the GRADE approach, 13, 15, 16, 18, 19 including allergen avoidance during pregnancy and lactation.
INTERVENTION STRATEGIES FOR PREVENTION OF FOOD ALLERGY
11-13 We do not discuss probiotics or fish oil further in this commentary, because the evidence for their effectiveness is of either indirect or low quality (Table III) and neither are widely recommended for food allergy prevention in most current guidelines.
